XML 105 R73.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaborative Arrangements and Licensing Agreements, Bayer (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Feb. 28, 2017 USD ($) PerformanceObligation | May 31, 2015 USD ($) PerformanceObligation | Jun. 30, 2015 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Revenue |  | $ 91,200 |  | $ 599,674 | $ 514,179 | $ 372,776
Deferred revenue |  |  |  |  | 233,362 |
R&D [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Revenue |  |  |  | 344,752 | 394,165 | $ 350,009
Bayer [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Deferred revenue |  |  |  | $ 4,300 | $ 9,300 |
Bayer [Member] | Revenue [Member] | Strategic Partner [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Concentration percentage |  |  |  | 1.00% | 13.00% | 1.00%
Bayer [Member] | R&D [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Revenue |  |  |  | $ 5,000 | $ 67,100 | $ 5,400
Bayer [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Upfront payment received |  | $ 100,000 | $ 100,000 |  |  |
Maximum amount of payments receivable for license fees and substantive milestones |  |  |  | 385,000 |  |
Maximum amount of payments receivable for development milestones |  |  |  | 125,000 |  |
Maximum amount of payments receivable for commercialization milestones |  |  |  | $ 110,000 |  |
Royalty percentage received on gross margins of both drugs combined |  |  |  | 20.00% |  |
Cumulative payments received |  |  |  | $ 175,000 |  |
Next prospective milestone |  |  |  | $ 10,000 |  |
Number of separate performance obligations | PerformanceObligation |  | 3 |  |  |  |
Transaction price |  | $ 100,000 |  |  |  |
Bayer [Member] | IONIS-FXI [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Transaction price |  | 91,200 |  |  |  |
Bayer [Member] | R&D Services for IONIS-FXI [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Transaction price |  | 4,300 |  |  |  |
Bayer [Member] | IONIS-FXI API [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Transaction price |  | $ 4,500 |  |  |  |
Bayer [Member] | R&D Services for IONIS-FXI-L [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Transaction price | $ 10,100 |  |  |  |  |
Bayer [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Payment received for advancing programs | $ 75,000 |  |  |  |  |
Number of separate performance obligations | PerformanceObligation | 3 |  |  |  |  |
Transaction price | $ 75,000 |  |  |  |  |
Number of new performance obligations | PerformanceObligation | 2 |  |  |  |  |
Bayer [Member] | IONIS-FXI-L [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Transaction price | $ 64,900 |  |  |  |  |
Number of new performance obligations | PerformanceObligation | 1 |  |  |  |  |
Bayer [Member] | R&D Services for IONIS-FXI-L [Member] |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |
Number of new performance obligations | PerformanceObligation | 1 |  |  |  |  |

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period. + References No definition available. + Details
Name: | ions_CumulativePaymentsReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for commercialization milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for development milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for license fees and substantive milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The next potential milestone payment to be earned under the collaboration agreement. + References No definition available. + Details
Name: | ions_NextPotentialMilestonePayment
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of payments received during the period for advancing programs under the collaboration agreement. + References No definition available. + Details
Name: | ions_PaymentReceivedForAdvancingPrograms
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of new performance obligations identified under the collaboration agreement. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of separate performance obligations under the collaboration agreement. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of consideration the Company is eligible to earn under the collaboration agreement, including any variable consideration. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerTransactionPrice
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The royalty percentage received on gross margins of drug(s) under the collaborative arrangement. + References No definition available. + Details
Name: | ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement
Namespace Prefix: | ions_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront payments received during the period under the collaboration agreement. + References No definition available. + Details
Name: | ions_UpfrontPaymentReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_IONISFXIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForIONISFXIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_IONISFXIActivePharmaceuticalIngredientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForIONISFXILMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_IONISFXILMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |